Pod24 and cr30 are promising surrogate endpoints for assessing the outcome of patients with advanced stage follicular lymphoma enrolled in the foll05 trial by fil.S. Luminari,L. Marcheselli,M. Manni,A. Anastasia,U. Vitolo,A. Chiarenza,L. Rigacci, E. Angelucci,A. Fama,A. Pulsoni,S. Rattotti, F. Angrilli, G. Gaidano,C. Stelitano,G. Bertoldero, N. Cascavilla, F. Salvi, A.J. Ferreri, V. Tarantino,M. Bellei, M. FedericoHematological Oncology（2017）引用 4|浏览78暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
